Cancer Heterogeneity Lab, CIC bioGUNE, BRTA, Technological Park Bizkaia, 801 A, Derio, Spain.
Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
Cell Commun Signal. 2024 Sep 2;22(1):425. doi: 10.1186/s12964-024-01800-w.
Increased cancer stem cell (CSC) content and SOX2 overexpression are common features in the development of resistance to therapy in hormone-dependent breast cancer, which remains an important clinical challenge. SOX2 has potential as biomarker of resistance to treatment and as therapeutic target, but targeting transcription factors is also challenging. Here, we examine the potential inhibitory effect of different polyoxometalate (POM) derivatives on SOX2 transcription factor in tamoxifen-resistant breast cancer cells.
Various POM derivatives were synthesised and characterised by infrared spectra, powder X-ray diffraction pattern and nuclear magnetic resonance spectroscopy. Estrogen receptor (ER) positive breast cancer cells, and their counterparts, which have developed resistance to the hormone therapy tamoxifen, were treated with POMs and their consequences assessed by gel retardation and chromatin immunoprecipitation to determine SOX2 binding to DNA. Effects on proliferation, migration, invasion and tumorigenicity were monitored and quantified using microscopy, clone formation, transwell, wound healing assays, flow cytometry and in vivo chick chorioallantoic membrane (CAM) models. Generation of lentiviral stable gene silencing and gene knock-out using CRISPR-Cas9 genome editing were applied to validate the inhibitory effects of the selected POM. Cancer stem cell subpopulations were quantified by mammosphere formation assays, ALDEFLUOR activity and CD44/CD24 stainings. Flow cytometry and western blotting were used to measure reactive oxygen species (ROS) and apoptosis.
POMs blocked in vitro binding activity of endogenous SOX2. [PWO] (PW) Wells-Dawson-type anion was the most effective at inhibiting proliferation in various cell line models of tamoxifen resistance. 10 µM PW also reduced cancer cell migration and invasion, as well as SNAI2 expression levels. Treatment of tamoxifen-resistant cells with PW impaired tumour formation by reducing CSC content, in a SOX2-dependent manner, which led to stem cell depletion in vivo. Mechanistically, PW induced formation of reactive oxygen species (ROS) and inhibited Bcl-2, leading to the death of tamoxifen-resistant cells. PW-treated tamoxifen-resistant cells showed restored sensitivity to tamoxifen.
Together, these observations highlight the potential use of PW as a SOX2 inhibitor and the therapeutic relevance of targeting SOX2 to treat tamoxifen-resistant breast cancer.
在激素依赖性乳腺癌中,癌症干细胞(CSC)含量增加和 SOX2 过表达是对治疗产生耐药性的常见特征,这仍然是一个重要的临床挑战。SOX2 有作为治疗耐药性的生物标志物和治疗靶点的潜力,但靶向转录因子也具有挑战性。在这里,我们研究了不同多金属氧酸盐(POM)衍生物对他莫昔芬耐药乳腺癌细胞中 SOX2 转录因子的潜在抑制作用。
通过红外光谱、粉末 X 射线衍射图和核磁共振谱对各种 POM 衍生物进行合成和表征。用 POM 处理雌激素受体(ER)阳性乳腺癌细胞及其对激素治疗他莫昔芬产生耐药性的对应细胞,并通过凝胶阻滞和染色质免疫沉淀来评估 SOX2 与 DNA 的结合情况,以确定其后果。通过显微镜、克隆形成、Transwell、划痕愈合试验、流式细胞术和体内鸡胚绒毛尿囊膜(CAM)模型监测和量化增殖、迁移、侵袭和致瘤性。应用 CRISPR-Cas9 基因组编辑生成慢病毒稳定基因沉默和基因敲除,以验证所选 POM 的抑制作用。通过类器官形成试验、ALDEFLUOR 活性和 CD44/CD24 染色来定量癌症干细胞亚群。流式细胞术和 Western blot 用于测量活性氧(ROS)和细胞凋亡。
POM 阻断了内源性 SOX2 的体外结合活性。[PWO](PW)Wells-Dawson 型阴离子在各种他莫昔芬耐药细胞模型中最有效地抑制增殖。10 µM PW 还降低了癌细胞的迁移和侵袭能力,以及 SNAI2 的表达水平。PW 处理他莫昔芬耐药细胞通过减少 SOX2 依赖性肿瘤形成来减少 CSC 含量,从而导致体内干细胞耗竭。在机制上,PW 诱导活性氧(ROS)的形成并抑制 Bcl-2,导致他莫昔芬耐药细胞死亡。PW 处理的他莫昔芬耐药细胞对他莫昔芬的敏感性恢复。
综上所述,这些观察结果强调了 PW 作为 SOX2 抑制剂的潜在用途,以及靶向 SOX2 治疗他莫昔芬耐药性乳腺癌的治疗相关性。